BrightSpring Health Services (BTSG) Stock News

BrightSpring Health Services (NASDAQ: BTSG) reported preliminary Q3 2025 continuing-operations results and raised full-year 2025 guidance on Oct 20, 2025. Q3 revenues were approximately $3,334M (+28.2% YoY) and Adjusted EBITDA was ~$160M (+37.2% YoY). Q3 net income was ~$37.5M versus a loss of ~$25.7M in Q3 2024. The Company increased 2025 guidance to $12.4B–$12.7B revenue and $605M–$615M Adjusted EBITDA, excluding the Community Living business and future closed acquisitions.

Other items: pharmacy segment revenue led growth (~$2,967M Q3), leverage was ~3.31x at Sept 30, 2025, and the Company expects the Community Living divestiture to close in early Q1 2026.

BrightSpring Health Services (NASDAQ: BTSG) said it will release Q3 2025 financial results on Friday, October 31, 2025 before an earnings conference call scheduled for 8:30 a.m. ET the same day. Investors can register to participate and a live and archived webcast will be available on the company's investor relations site under Events & Presentations, where related presentation materials will be posted prior to the call.

BrightSpring Health Services (NASDAQ: BTSG) reported strong Q2 2025 financial results, with net revenue reaching $3.148 billion, up 29.1% year-over-year. The company's Adjusted EBITDA grew 28.8% to $143 million, while net income from continuing operations remained flat at $8.5 million.

The company's performance was driven by significant growth in both segments: Pharmacy Solutions revenue increased 32% to $2.79 billion, while Provider Services revenue grew 11% to $358 million. Following these results, BrightSpring raised its full-year 2025 guidance, now expecting revenue between $12.2-$12.6 billion (21.1-25.1% growth) and Adjusted EBITDA of $590-$605 million (28.2-31.5% growth).

Additionally, BrightSpring's planned divestiture of its Community Living business to Sevita, announced in January 2025, is expected to complete in Q4 2025.

BrightSpring Health Services (NASDAQ: BTSG) has scheduled its second quarter 2025 financial results announcement for August 1, 2025. The company will release its earnings before the market opens, followed by a conference call at 8:30 a.m. ET on the same day.

Interested participants can register for the conference call online. The company will also provide a live and archived webcast of the call on its investor relations website, along with related presentation materials.

BrightSpring Health Services (NASDAQ: BTSG) announced that its specialty pharmacy subsidiary Onco360® has been selected as the national pharmacy partner for multiple new cancer and rare disease treatments. The partnership covers three newly approved therapies: GOMEKLI for neurofibromatosis type 1 patients with plexiform neurofibromas, AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer, and IBTROZI for ROS1-positive non-small cell lung cancer. This expansion strengthens Onco360's position as a leading independent specialty pharmacy in providing access, education, data, and expert support for innovative treatments targeting serious and life-threatening conditions.

BrightSpring Health Services (NASDAQ: BTSG) has announced the pricing of a secondary offering of 14 million shares of common stock at $21.75 per share by its existing stockholders, including KKR affiliates and management members. The KKR Selling Stockholder has provided underwriters a 30-day option to purchase an additional 2.1 million shares. BrightSpring will not receive any proceeds from the offering, as all proceeds will go to the Selling Stockholders. The offering is expected to close on June 12, 2025. Goldman Sachs, BofA Securities, Jefferies, and Morgan Stanley are leading the offering as book-running managers, with KKR Capital Markets acting as lead managing agent. Multiple other financial institutions are participating as bookrunners and co-managers.

BrightSpring Health Services (NASDAQ: BTSG) announced a secondary offering where certain stockholders, including KKR affiliates and management members, plan to sell 14 million shares of common stock. The KKR Selling Stockholder will grant underwriters a 30-day option to purchase an additional 2.1 million shares. BrightSpring will not sell any shares or receive proceeds from this offering. Goldman Sachs and BofA Securities are leading the offering as book-running managers, with KKR Capital Markets acting as lead managing agent. The offering will be made through a shelf registration statement filed with the SEC on June 10, 2025.

BrightSpring Health Services (NASDAQ: BTSG) reported strong Q1 2025 financial results and raised its full-year guidance. The company achieved Q1 net revenue of $2.878 billion, up 25.9% year-over-year, and turned around from a loss to net income of $9.2 million. Adjusted EBITDA grew 28.2% to $131 million. The Pharmacy Solutions segment led growth with revenue up 28% to $2.532 billion, while Provider Services revenue increased 12% to $346 million. BrightSpring increased its 2025 guidance, now expecting revenue of $12-12.5 billion (19.1-24.1% growth) and adjusted EBITDA of $570-585 million (23.9-27.2% growth). The company's planned divestiture of its Community Living business to Sevita remains on track for completion this year.

BrightSpring Health Services (NASDAQ: BTSG) has scheduled the release of its first quarter 2025 financial results for Friday, May 2, 2025. The announcement will be made before the company's earnings conference call, which is set for 8:30 a.m. ET on the same day.

Interested participants can register for the conference call prior to the 8:30 a.m. ET start time. The company will make both a live and archived webcast available on their investor relations website at ir.brightspringhealth.com under the 'Events & Presentations' section, where related presentation materials will also be posted before the call.